```html

Xanthopsia (Migraine Aura)

What is Xanthopsia (migraine aura)?

Xanthopsia is a visual disturbance in which objects appear tinted yellow. When it occurs as part of a migraine aura, the yellow‑tinged vision is transient, lasting from a few minutes up to an hour, and is usually followed or accompanied by the headache phase of a migraine. Aura phenomena are thought to arise from a wave of cortical spreading depression—a brief, intense depolarisation of neurons—in the visual cortex. This wave temporarily disrupts normal visual processing, leading to colour distortions, flashes of light, blind spots, or, in the case of xanthopsia, a pervasive yellow hue.<sup>1</sup>

While xanthopsia is less common than the classic “zig‑zag” scintillating scotoma, it is a recognised subtype of migraine aura and can be distressing because the colour change is often vivid and can affect both eyes simultaneously. Understanding its causes, associated symptoms, and when to seek professional help is essential for anyone who experiences this phenomenon.

Common Causes

The following conditions are most frequently linked to xanthopsia, either as a primary migraine aura or as a secondary cause that mimics the aura:

• Migraine with aura – the classic cause; cortical spreading depression triggers yellow visual tint.
• Medication‑induced visual changes – especially digitalis (digoxin), quinine, and some antibiotics (e.g., chloroquine).
• Retinal or optic nerve disease – optic neuritis, retinal detachment, or macular degeneration can alter colour perception.
• Transient ischemic attack (TIA) or stroke – especially in the occipital lobe, may produce sudden colour shifts.
• Metabolic disturbances – severe liver disease, jaundice, or hyperbilirubinemia can give a yellow tinge to vision.
• Neurological disorders – multiple sclerosis lesions affecting the visual pathway.
• Brain tumor or space‑occupying lesion – compressing visual cortex.
• Infectious or inflammatory conditions – encephalitis, meningitis, or autoimmune encephalopathy.
• Vitamin deficiencies – especially vitamin A or B12 deficiencies that affect retinal function.
• Exposure to certain chemicals – organophosphates, lead, or nitrobenzene can produce colour vision changes.

Associated Symptoms

When xanthopsia appears as part of a migraine aura, it is often accompanied by other neurological or sensory signs. Commonly reported associations include:

• Flashing lights or scintillating scotomas (zig‑zag lines).
• Blurred vision or temporary loss of visual field (negative aura).
• Seeing “floaters,” spots, or objects appearing larger/smaller.
• Vertigo or a sense of disequilibrium.
• Numbness or tingling in the face, arms, or legs.
• Speech difficulties (aphasia) or difficulty finding words.
• Headache that develops 5–60 minutes after aura onset, often throbbing and unilateral.
• Nausea, vomiting, and heightened sensitivity to light (photophobia) or sound (phonophobia).
• Fatigue or a “brain fog” feeling after the aura resolves.

When to See a Doctor

While migraine aura is usually benign, certain patterns warrant prompt medical evaluation:

• Aura lasting longer than 60 minutes or progressively worsening.
• Sudden onset of visual changes without a prior migraine history.
• Accompanying neurological deficits such as weakness, difficulty speaking, or loss of coordination.
• Headache that is the worst you’ve ever experienced (a “thunderclap” headache).
• Recent head trauma, infection, or new medication introductions.
• Signs of jaundice (yellowing of skin/eyes) suggesting systemic causes.
• Any visual change that occurs while driving or operating machinery.

If any of these red‑flag features are present, seek medical care immediately.

Diagnosis

Diagnosing xanthopsia involves a structured history, physical examination, and targeted investigations to rule out secondary causes.

1. Detailed History

• Onset, duration, and frequency of the yellow‑tinted vision.
• Presence of typical migraine triggers (stress, hormonal changes, specific foods).
• Medication review – including over‑the‑counter drugs and supplements.
• Associated symptoms (headache, nausea, neurological deficits).
• Family history of migraine or neurological disease.

2. Physical and Neurological Examination

• Vision testing (visual acuity, colour discrimination tests such as Ishihara plates).
• Fundoscopic examination to assess the retina and optic disc.
• Full neurologic exam to detect subtle motor, sensory, or speech changes.

3. Laboratory Tests (when indicated)

• Complete blood count and metabolic panel to rule out liver dysfunction or electrolyte abnormalities.
• Liver function tests (ALT, AST, bilirubin) if jaundice is suspected.
• Serum digoxin level if the patient is on cardiac glycosides.
• Vitamin A and B12 levels if deficiencies are considered.

4. Imaging Studies

• Magnetic Resonance Imaging (MRI) of the brain with contrast – preferred for detecting cortical lesions, tumors, or demyelination.
• CT scan – fast screening tool in emergency settings for acute hemorrhage or stroke.
• Magnetic Resonance Angiography (MRA) or CT Angiography – if vascular causes like TIA are suspected.

5. Specialized Visual Testing

• Electroretinography (ERG) – evaluates retinal function.
• Visual evoked potentials (VEP) – assesses conduction through the optic pathway.

Treatment Options

Treatment is aimed at aborting the migraine attack, preventing future auras, and addressing any underlying secondary cause.

Acute Migraine‑Related Xanthopsia

• Triptans (sumatriptan, rizatriptan) – most effective when taken early in the aura phase.
• NSAIDs (ibuprofen, naproxen) – reduce inflammation and pain.
• Anti‑nausea agents (metoclopramide, prochlorperazine) – helpful for associated nausea.
• Ergots (dihydroergotamine) – an alternative for patients who cannot use triptans.
• Oxygen therapy – 100 % oxygen delivered at 6–10 L/min for 15‑20 minutes may help in some cases.

Preventive (Prophylactic) Therapies

• Beta‑blockers (propranolol, metoprolol) – first‑line for frequent migraines.
• Calcium‑channel blockers (verapamil) – especially useful when aura is dominant.
• Antidepressants (amitriptyline, venlafaxine) – benefit patients with comorbid mood disorders.
• Anticonvulsants (topiramate, valproic acid) – effective in reducing aura frequency.
• CGRP monoclonal antibodies (erenumab, fremanezumab) – newer agents with favorable side‑effect profiles.
• Magnesium supplementation – 400‑600 mg daily can lessen aura intensity in some patients.
• Riboflavin (Vitamin B2) – 400 mg daily shown to reduce migraine days.

Treatment of Secondary Causes

• Discontinue or adjust offending medications (e.g., digitalis, quinine).
• Treat liver disease or correct hyperbilirubinemia.
• Manage vascular risk factors and address TIAs with antiplatelet therapy.
• Immunomodulatory therapy for multiple sclerosis lesions.
• Surgical or laser interventions for retinal detachments or optic nerve compression.

Prevention Tips

Even if you have established migraine patterns, lifestyle modifications can dramatically lower the frequency and severity of aura, including xanthopsia.

• Identify and avoid triggers: keep a migraine diary to spot foods, stressors, or sleep changes that precede an aura.
• Maintain regular sleep hygiene: aim for 7‑9 hours per night, go to bed and wake at consistent times.
• Stay hydrated: dehydration is a common precipitant; target at least 2 L of water daily.
• Exercise regularly: moderate aerobic activity (30 minutes, 3‑5 times per week) reduces migraine frequency.
• Limit caffeine and alcohol: excessive intake can trigger aura; consider a gradual reduction.
• Manage stress: biofeedback, mindfulness meditation, yoga, or cognitive‑behavioral therapy have proven benefits.
• Protect eyes from bright light: wear sunglasses with UV protection and consider blue‑light filtering lenses when using screens.
• Review medications annually: discuss with a pharmacist or physician any drugs that could affect colour perception.
• Adhere to preventive medication schedules: missing doses can lead to breakthrough auras.

Emergency Warning Signs

Key Take‑aways

Xanthopsia, or yellow‑tinted vision, can be an unsettling component of migraine aura. While most cases are benign and respond to standard migraine therapies, the symptom can also herald more serious conditions such as stroke, retinal disease, or medication toxicity. A thorough clinical assessment, appropriate imaging, and a tailored treatment plan—combined with lifestyle‑based prevention—are the cornerstones of effective management.

If you notice persistent yellow vision or any of the emergency warning signs listed above, do not wait—contact a medical professional or head to the nearest emergency department.

---

References:

1. Mayo Clinic. “Migraine with aura.” https://www.mayoclinic.org. Accessed May 2024.
2. American Academy of Neurology. “Cortical spreading depression and migraine aura.” https://www.aan.com. 2023.
3. National Institutes of Health – National Library of Medicine. “Xanthopsia.” PubMed. 2022.
4. World Health Organization. “Headache disorders.” WHO Fact Sheet. 2022.
5. Cleveland Clinic. “Migraine treatment options.” https://my.clevelandclinic.org. 2024.

```